Dr. Sekeres discusses the current unmet needs of patients with higher-risk myelodysplastic syndromes receiving hypomethylating agents, the potential utility of novel combinations in development, and the incorporation of other end points beyond overall survival in clinical trials.

S5 Ep37: Sekeres Previews Potential Combination Strategies in HR-MDS

<p>In OncLive® On Air, you can expect to hear interviews with academic oncologists on the thought-provoking oncology presentations they give at the OncLive® State of the Science Summits. The topics in oncology vary, from systemic therapies, surgery, radiation therapy, to emerging therapeutic approaches in a particular type of cancer. This includes lung cancer, breast cancer, gastrointestinal cancers, hematologic malignancies, gynecologic cancers, genitourinary cancers, and more.</p>

Science

Health & Fitness

In OncLive® On Air, you can expect to hear interviews with academic oncologists on the thought-provoking oncology presentations they give at the OncLive® State of the Science Summits. The topics in oncology vary, from systemic therapies, surgery, radiation therapy, to emerging therapeutic approaches in a particular type of cancer. This includes lung cancer, breast cancer, gastrointestinal cancers, hematologic malignancies, gynecologic cancers, genitourinary cancers, and more.

Share S5 Ep37: Sekeres Previews Potential Combination Strategies in HR-MDS

Sign up to save your podcasts

S5 Ep37: Sekeres Previews Potential Combination Strategies in HR-MDS

S5 Ep37: Sekeres Previews Potential Combination Strategies in HR-MDS

More shows like OncLive® On Air

Left, Right & Center

The Ben Shapiro Show

NEJM This Week

Nature Podcast

Research To Practice | Oncology Videos

ASCO Daily News

Audio Journal of Oncology Podcast

OncoPharm

ASCO Guidelines

The Uromigos

Simple English News Daily

Oncology Today with Dr Neil Love

People I (Mostly) Admire

Oncology Brothers: Practice-Changing Cancer Discussions

English Learning Podcast